Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Risks of Opana Extended Release

Michele B. Kaufman, PharmD, BCGP  |  April 17, 2017

At a two-day joint meeting of the U.S. Food and Drug Administration‘s (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and the Drug Safety and Risk Management Advisory Committee (DSARM), committee members voted 18–8, with one abstention, that the benefits of Opana ER (oxymorphone hydrochloride) do not outweigh its public health risks.1 The health risks include recent HIV and hepatitis C virus (HCV) outbreaks, as well as vascular issues, related to intravenous abuse of this drug. An HIV outbreak in Scott County, Ind., which resulted from needle sharing among patients co-infected with HCV and HIV, has been linked to intravenous Opana use.2

Opana has a turbulent FDA regulatory history. The treatment was originally approved in 2006 to treat chronic pain. In 2011, the manufacturer, Endo Pharmaceuticals, reformulated the drug to make it harder to abuse. However, the new formulation never won abuse-deterrent labeling from the FDA. The manufacturer was also unable to stop generic versions of its initial formulation from becoming available, despite claiming the new version was safer. After the reformulation, 15 cases of thrombotic thrombocytopenic purpura were reported among injection-drug users who had recently injected reformulated Opana ER. This outbreak occurred in Tennessee in 2012 and was evaluated by and reported on by the Centers for Disease Control and Prevention.3 Additional case reports have been published.4

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A number of FDA Advisory Committee members expressed their preference that the drug remain on the market with additional regulatory restrictions to mitigate its risks. Most of the panelists felt that revising and resubmitting the drug’s New Drug Application may resolve these issues. The manufacturer remains committed to reducing the potential abuse, misuse and diversion of its products.5


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Fiore K. FDA joint panel votes down Opana ER: Too many risks with reformulated version tied to HIV, TTP clusters. 2017 Mar 15.
  2. Centers for Disease Control and Prevention. Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone—Indiana, 2015. MMWR. 2015 May 1;64(16):443–444.
  3. Centers for Disease Control and Prevention. Thrombotic thrombocytopenic purpura (TTP)-like illness associated with intravenous Opana ER abuse-Tennessee, 2012. MMWR. 2013 Jan 11;62(01):1–4.
  4. Miller PJ, Farland AM, Knovich MA, et al. Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange. Am J Hematol. 2014 Jul;89(7):695–697. doi: 10.1002/ajh.23720. Epub 2014 Apr 15.
  5. Endo International Plc. News release: Endo statement on FDA advisory committees’ vote related to Opana ER. 2017 Mar 14.

Page: 1 2 | Single Page
Share: 

Filed under:AnalgesicsDrug Updates Tagged with:FDAFood and Drug AdministrationOpana EROpioid abuseOpioidspublic health

Related Articles
    Rheumatologists Treating Patients with HIV Face Treatment, Diagnostic Challenges

    Rheumatologists Treating Patients with HIV Face Treatment, Diagnostic Challenges

    June 15, 2017

    Rheumatologists treating HIV patients in 2017 must think through many important factors as this population ages. As we continue to learn, rheumatologists must consider important drug–drug interactions, relatively uncommon rheumatological presentations of HIV, as well as specific diagnostic challenges. Working closely with infectious disease specialists is the best way to achieve optimum care for this…

    HIV Infection: What Rheumatologists Need to Know

    HIV Infection: What Rheumatologists Need to Know

    June 15, 2015

    It has been nearly 35 years since the original descriptions of what now is recognized as AIDS (the acquired immune deficiency syndrome), an advanced form of infection secondary to the human immunodeficiency virus (HIV). The epidemic of HIV infection remains the singular most dramatic epidemic of our generation and will likely remain with us for…

    FDA Requests Removal of Opana ER; Plus Abatacept’s New Dosing Option

    June 21, 2017

    The FDA has asked the manufactures of Opana ER to remove the opioid from the U.S. market due to the public health risk of abuse…

    Opana ER Pulled from U.S. Market

    July 11, 2017

    Endo Pharmaceuticals will work with the FDA to coordinate the organized removal of Opana ER from the U.S. market.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences